Fusaritricins E–G, three new polyketides, isolated from the endophytic fungus Fusarium sp. HC20 and their antifungal activities

IF 1.4 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-07-29 DOI:10.1016/j.phytol.2025.103016

Xu-Ri Wan , Chang Li , Ling-Yan Liu , Fang Yue , Xuan Lu , Yue-Hu Pei , Yi-Hui Yang

引用次数: 0

Abstract

Three previously undescribed polyketides, fusaritricins E-G (1–3), along with eight known ones (4–11), were isolated from the endophytic fungus Fusarium sp. HC20 derived from the root of Rhodiola rosea L. Their chemical structures, including the absolute configurations, were elucidated through comprehensive spectroscopic analysis, such as HR-ESI-MS, 1D NMR, 2D NMR and ECD. Compounds 1–9 were evaluated for their antifungal activities against Candida albicans CMCC 98001 and Aspergillus niger R330. The results indicated that 1 and 2 exhibited bioactivities against C. albicans comparable to the positive control caspofungin, with MIC values of 12.5 μg/mL.

查看原文本刊更多论文

Fusaritricins E-G：从内生真菌Fusarium sp. HC20中分离的3个新聚酮化合物及其抗真菌活性

从红景天（Rhodiola rosea L.）根内生真菌Fusarium sp. HC20中分离得到3个先前未被发现的多酮类化合物fusaritricins E-G（1-3）和8个已知的多酮类化合物（4-11），并通过HR-ESI-MS、1D NMR、2D NMR和ECD等综合波谱分析对它们的化学结构和绝对构型进行了鉴定。研究了化合物1 ~ 9对白色念珠菌cmcc98001和黑曲霉R330的抑菌活性。结果表明，1和2具有与阳性对照caspofungin相当的抗白色念珠菌活性，MIC值为12.5 μg/mL。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.